These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 22487859)

  • 1. Laforin and malin deletions in mice produce similar neurologic impairments.
    García-Cabrero AM; Marinas A; Guerrero R; de Córdoba SR; Serratosa JM; Sánchez MP
    J Neuropathol Exp Neurol; 2012 May; 71(5):413-21. PubMed ID: 22487859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
    DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
    J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.
    López-González I; Viana R; Sanz P; Ferrer I
    Mol Neurobiol; 2017 Jul; 54(5):3119-3130. PubMed ID: 27041370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.
    Sánchez-Elexpuru G; Serratosa JM; Sánchez MP
    Epilepsia; 2017 Mar; 58(3):467-475. PubMed ID: 28098937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
    Zeng L; Wang Y; Baba O; Zheng P; Liu Y; Liu Y
    FEBS J; 2012 Jul; 279(14):2467-78. PubMed ID: 22578008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epm2a
    Burgos DF; Sciaccaluga M; Worby CA; Zafra-Puerta L; Iglesias-Cabeza N; Sánchez-Martín G; Prontera P; Costa C; Serratosa JM; Sánchez MP
    Neurobiol Dis; 2023 Jun; 181():106119. PubMed ID: 37059210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.
    Gayarre J; Duran-Trío L; Criado Garcia O; Aguado C; Juana-López L; Crespo I; Knecht E; Bovolenta P; Rodríguez de Córdoba S
    Brain; 2014 Mar; 137(Pt 3):806-18. PubMed ID: 24430976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy.
    Criado O; Aguado C; Gayarre J; Duran-Trio L; Garcia-Cabrero AM; Vernia S; San Millán B; Heredia M; Romá-Mateo C; Mouron S; Juana-López L; Domínguez M; Navarro C; Serratosa JM; Sanchez M; Sanz P; Bovolenta P; Knecht E; Rodriguez de Cordoba S
    Hum Mol Genet; 2012 Apr; 21(7):1521-33. PubMed ID: 22186026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced sensitivity of laforin- and malin-deficient mice to the convulsant agent pentylenetetrazole.
    García-Cabrero AM; Sánchez-Elexpuru G; Serratosa JM; Sánchez MP
    Front Neurosci; 2014; 8():291. PubMed ID: 25309313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
    Ganesh S; Delgado-Escueta AV; Sakamoto T; Avila MR; Machado-Salas J; Hoshii Y; Akagi T; Gomi H; Suzuki T; Amano K; Agarwala KL; Hasegawa Y; Bai DS; Ishihara T; Hashikawa T; Itohara S; Cornford EM; Niki H; Yamakawa K
    Hum Mol Genet; 2002 May; 11(11):1251-62. PubMed ID: 12019206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for Lafora disease in the Epm2a
    Zafra-Puerta L; Iglesias-Cabeza N; Burgos DF; Sciaccaluga M; González-Fernández J; Bellingacci L; Canonichesi J; Sánchez-Martín G; Costa C; Sánchez MP; Serratosa JM
    Mol Ther; 2024 Jul; 32(7):2130-2149. PubMed ID: 38796707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and Functional Brain Abnormalities in Mouse Models of Lafora Disease.
    Burgos DF; Cussó L; Sánchez-Elexpuru G; Calle D; Perpinyà MB; Desco M; Serratosa JM; Sánchez MP
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
    Couarch P; Vernia S; Gourfinkel-An I; Lesca G; Gataullina S; Fedirko E; Trouillard O; Depienne C; Dulac O; Steschenko D; Leguern E; Sanz P; Baulac S
    J Mol Med (Berl); 2011 Sep; 89(9):915-25. PubMed ID: 21505799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of laforin or malin results in increased Drp1 level and concomitant mitochondrial fragmentation in Lafora disease mouse models.
    Upadhyay M; Agarwal S; Bhadauriya P; Ganesh S
    Neurobiol Dis; 2017 Apr; 100():39-51. PubMed ID: 28063983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
    Tiberia E; Turnbull J; Wang T; Ruggieri A; Zhao XC; Pencea N; Israelian J; Wang Y; Ackerley CA; Wang P; Liu Y; Minassian BA
    J Biol Chem; 2012 Jul; 287(30):25650-9. PubMed ID: 22669944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.
    Spuch C; Ortolano S; Navarro C
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):99-107. PubMed ID: 22369717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease.
    Sánchez-Elexpuru G; Serratosa JM; Sanz P; Sánchez MP
    Neuroreport; 2017 Mar; 28(5):268-271. PubMed ID: 28181916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in lafora progressive myoclonus epilepsy.
    Delgado-Escueta AV
    Curr Neurol Neurosci Rep; 2007 Sep; 7(5):428-33. PubMed ID: 17764634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.
    Ortolano S; Vieitez I; Agis-Balboa RC; Spuch C
    Mol Brain; 2014 Jan; 7():7. PubMed ID: 24472629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.